TY - JOUR AU - Galer, Erika L. AU - Grace, Peter M. PY - 2015 TI - Reactive aldehydes: a new player in inflammatory pain JF - Annals of Translational Medicine; Vol 3, Supplement 1 (May 15, 2015): Annals of Translational Medicine Y2 - 2015 KW - N2 - Pain is a costly problem worldwide. USA expenditures on pain are higher than those for cancer, heart disease, and diabetes combined, at approximately $560 billion annually (1). As noted recently (2), pain therapeutics are dominated by well-established drug classes that are focused on symptom reduction, and are plagued by limited efficacy and/or significant adverse effects. NSAID’s are used to treat acute pain and are accompanied by risk of cardiovascular damage, liver damage, kidney damage, and delayed bone healing (3). COX-2 inhibitors have limited efficacy and can cause cardiovascular problems (4,5). Mechanism-based treatments that are individualized to patients with particular underlying pathophysiology have long remained the goal for preclinical and clinical researchers alike (6,7). In a recent article, Zambelli et al. (8) document their discovery of a new mechanism of inflammatory pain that may lead us closer to a mechanism-based therapeutic approach. UR - https://atm.amegroups.org/article/view/6415